Skip to main content
. 2020 Nov 23;261:113–122. doi: 10.1016/j.jss.2020.10.032

Table 1.

Patient demographics, comorbidities, and preoperative COVID-19 course.

Characteristics n (%) Symptoms/Comorbidities n (%)
Patients 39 Preoperative symptoms
Gender  Any preoperative COVID-19 symptoms 20 (51.3%)
 Male 22 (56.4%)  Cough 10 (25.6%)
 Female 17 (43.6%)  Objective fever 10 (25.6%)
Age (years) 53.92 ± 20.30  Fatigue/malaise 4 (10.3%)
BMI (kg/m2) 26.89 ± 8.19  Shortness of breath 5 (12.8%)
Race/ethnicity  Myalgia or arthralgia 1 (2.6%)
 Caucasian 6 (15.4%)  Anosmia or abnormal smell 0
 African American 5 (12.8%)  Ageusia or abnormal taste 1 (2.6%)
 Hispanic/Latinx 18 (46.2%)
 Asian 0
 Other/not reported 10 (25.6%) Preoperative testing/workup
Living situation  Preoperative positive COVID-19 test 22 (56.4%)
 House/apartment 28 (71.8%)  Preoperative admission for COVID-19 3 (7.7%)
 Shelter-domiciled/homeless 6 (15.4%)  Preoperative ICU for COVID-19 1 (2.6%)
 Long-term facility 3 (7.7%)  Radiologic evidence of pneumonia
 Incarcerated 2 (5.1%)  X-ray 15 (38.5%)
Tobacco use  CT scan 6 (15.4%)
 Active 3 (8.8%)  Time from symptom onset to surgery (days) 14 ± 6 (range: 1-22)
 Former 5 (14.7%)  Time from positive COVID-19 test to surgery (days) 2.5 ± 12 (range: –33-24)
Hypertension 18 (46.2%)
Congestive heart failure 3 (7.7%)
Coronary artery disease 5 (12.8%) Pharmacologic management
Cerebrovascular accident 2 (5.1%)  Azithromycin 13 (33.3%)
COPD 5 (12.8%)  Hydroxychloroquine 17 (43.6%)
Diabetes mellitus 4 (10.3%)  Other antibiotics (excluding peri-operative) 28 (71.8%)
Chronic kidney disease 5 (12.8%)  Lopinavir-ritonavir 3 (7.7%)
Hemodialysis 4 (10.3%)  Remdesivir 0
Active malignancy 1 (2.6%)  Tocilizumab 0
History of malignancy 2 (5.1%)  Steroids 1 (2.6%)
Autoimmune disorder 1 (2.6%)  Immunoglobulin 0

BMI = body mass index; COPD = chronic obstructive pulmonary disease.

Mean ± Standard Deviation.

Only 1 patient in deceased group placed on ventilator postoperatively.